ERBB2 and sarcoma: In sarcoma models, miRNA-modified CAR T cells show promise because specific miRNAs like miR-34a can target multiple oncogenic pathways, including restoring p53, causing cell cycle arrest, and triggering apoptosis, while the CAR component ensures targeting of sarcoma-associated antigens like GD2, HER2, or tumor-specific neoantigens [175].